Validation of the Adolescent Pediatric Pain Tool for the Multidimensional Measurement of Pain in Children and Adolescents Diagnosed with Osteogenesis Imperfecta

doi:10.1080/24740527.2019.1626705

. 2019 Jul 18;3(1):148-156.

doi: 10.1080/24740527.2019.1626705. eCollection 2019.

Validation of the Adolescent Pediatric Pain Tool for the Multidimensional Measurement of Pain in Children and Adolescents Diagnosed with Osteogenesis Imperfecta

Madalina Boitor^{1

2}, Céline Gélinas^{1

2}, Frank Rauch^{3

4}, Eufemia Jacob⁵, Sylvie LeMay^{6

7}, Jaimie Isabel Carrier¹, Claudette Bilodeau⁴, Argerie Tsimicalis^{1

4}

Affiliations

¹ Ingram School of Nursing, McGill University, Montreal, Quebec, Canada.
² Centre for Nursing Research and Lady Davis Institute, CIUSSS Centre-Ouest-Ile-de-Montréal, Jewish General Hospital, Montréal, Québec, Canada.
³ Department of Pediatrics, McGill University, Montreal, Quebec, Canada.
⁴ Clinical Research, Shriners Hospitals for Children-Canada, Montreal, Quebec, Canada.
⁵ UCLA School of Nursing, University of California, Los Angeles, California, USA.
⁶ Faculty of Nursing, University of Montreal, Montreal, Quebec, Canada.
⁷ CHU Ste-Justine Research Centre, Centre hospitalier universitaire (CHU) Sainte-Justine, Montreal, Quebec, Canada.

PMID: 35005403
PMCID: PMC8730568
DOI: 10.1080/24740527.2019.1626705

Validation of the Adolescent Pediatric Pain Tool for the Multidimensional Measurement of Pain in Children and Adolescents Diagnosed with Osteogenesis Imperfecta

Madalina Boitor et al. Can J Pain. 2019.

. 2019 Jul 18;3(1):148-156.

doi: 10.1080/24740527.2019.1626705. eCollection 2019.

Authors

Madalina Boitor^{1

2}, Céline Gélinas^{1

2}, Frank Rauch^{3

4}, Eufemia Jacob⁵, Sylvie LeMay^{6

7}, Jaimie Isabel Carrier¹, Claudette Bilodeau⁴, Argerie Tsimicalis^{1

4}

Affiliations

¹ Ingram School of Nursing, McGill University, Montreal, Quebec, Canada.
² Centre for Nursing Research and Lady Davis Institute, CIUSSS Centre-Ouest-Ile-de-Montréal, Jewish General Hospital, Montréal, Québec, Canada.
³ Department of Pediatrics, McGill University, Montreal, Quebec, Canada.
⁴ Clinical Research, Shriners Hospitals for Children-Canada, Montreal, Quebec, Canada.
⁵ UCLA School of Nursing, University of California, Los Angeles, California, USA.
⁶ Faculty of Nursing, University of Montreal, Montreal, Quebec, Canada.
⁷ CHU Ste-Justine Research Centre, Centre hospitalier universitaire (CHU) Sainte-Justine, Montreal, Quebec, Canada.

PMID: 35005403
PMCID: PMC8730568
DOI: 10.1080/24740527.2019.1626705

Abstract
in English, French

Background: The Adolescent Pediatric Pain Tool (APPT) is a self-reported, multidimensional assessment of pain location, intensity, and quality in children and adolescents. Yet, it has not been validated for use in children and adolescents with osteogenesis imperfecta (OI). Aims: This study aimed to validate and evaluate the feasibility of the APPT for pain assessment in children and adolescents with OI. Methods: A prospective observational study was conducted at a university-affiliated pediatric hospital in Canada. Thirty-three children and adolescents with OI participated by completing the APPT pre-bisphosphonate intravenous infusion and 1 week post-bisphosphonate intravenous infusion. Main outcomes were internal consistency, convergent and discriminative validity, and feasibility. Results: The Kuder-Richardson test of internal consistency was 0.863, 0.661, and 0.729 for the Sensory, Affective, and Evaluative subscales, respectively. For the entire pain quality scale, the Cronbach's alpha was 0.835. Regarding convergent validity, a moderate correlation was observed between the ratings on the pain intensity scale and the Faces Pain Scale-Revised (Spearman's rho = 0.711). Patients for whom pain was a problem reported higher pain intensity (Mann Whitney U = 41.50, P = 0.032) and more pain quality descriptors (Mann Whitney U = 45.50, P = 0.020) and painful body areas (Mann-Whitney U = 25.50, P = 0.001) than those for whom it was not (Mann-Whitney U, P < 0.05). In terms of feasibility, completing the tool may require a considerable time commitment and assistance from a clinician or parent, especially if the patient is experiencing pain and provides detailed pain location and quality information by completing the APPT. Conclusions: This study suggests that the APPT is valid for the multidimensional assessment of pain in children and adolescents with OI, but feasibility needs to be enhanced.

Contexte: L’outil d’évaluation de la douleur des adolescents en pédiatrie (APPT) est une évaluation multidimensionnelle auto-déclarée de l’emplacement, de l’intensité et de la qualité de la douleur chez les enfants et les adolescents. Toutefois, l’utilisation de cet outil auprès des enfants et des adolescents souffrant d’ostéogénèse imparfaite n’a pas encore été validée.But: Cette étude avait pour but de valider et d’évaluer la faisabilité de l’APPT pour l’évaluation de la douleur dans cette population.Méthodes: Une étude observationnelle prospective a été menée dans un centre hospitalier universitaire à vocation pédiatrique au Canada. Trente-trois enfants et adolescents atteints d’ostéogénèse imparfaite ont participé à cette étude en répondant à l’APPT avant l’infusion intraveineuse de bisphosphonate et une semaine après celle-ci. Les principaux résultats étaient la cohérence interne, la validation convergente et discriminante, et la faisabilité.Résultats: Le résultat du test de Kuder-Richardson pour mesurer la cohérence interne était de 0,863 pour le sensoriel, 0,661 pour l’affectif et 0,729 pour les sous-échelles d’évaluation. Pour l’échelle de qualité de la douleur au complet, l’indice alpha de Cronbach était de 0,835. En ce qui concerne la validation convergente, une corrélation modérée a été observée entre les scores obtenus à l’échelle d’intensité de la douleur et le FPS-R (Rho de Spearman= 0,711). Les patients pour lesquels la douleur était problématique ont fait état d’une intensité de la douleur plus élevée, ont eu recours à un plus grand nombre de descripteurs de la qualité de la douleur et ont identifié davantage de parties du corps douloureuses que ceux pour lesquels la douleur n’était pas problématique (Mann-Whitney U, p < 0,05). En ce qui concerne la faisabilité, le temps requis pour répondre au questionnaire peut être considérable et l’aide d’un clinicien ou d’un parent peut être nécessaire, particulièrement si le patient ressent de la douleur et donne de l’information détaillée sur la localisation et la qualité de la douleur en répondant à l’APPT.Conclusions: Selon cette étude, l’APPT est valide pour l’évaluation multidimensionnelle de la douleur chez les enfants et les adolescens souffrant d’oastéogénèse imparfaite, mais sa faisabilité doit être améliorée.

Keywords: Psychometrics; orthopedic; pain assessment; pediatric pain.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the authors.

Figures

**Figure 1.**
Frequency of pain reports by children and adolescents with osteogenesis imperfecta measured using the body outline diagram (n = 33) prior to receiving bisphosphonate treatment.

See this image and copyright information in PMC

Cited by

A multicenter study to evaluate pain characteristics in osteogenesis imperfecta.
Rodriguez Celin M, Kruger KM, Caudill A, Murali CN, Nagamani SCS; Members of the Brittle Bone Disorders Consortium (BBDC); Smith PA, Harris GF. Rodriguez Celin M, et al. Am J Med Genet A. 2023 Jan;191(1):160-172. doi: 10.1002/ajmg.a.63009. Epub 2022 Oct 22. Am J Med Genet A. 2023. PMID: 36271817 Free PMC article.
The Design, Development, and Usability Testing of an eHealth Program for Youths With Osteogenesis Imperfecta: Protocol for a 2-Phase User-Centered Mixed Methods Study.
Tsimicalis A, Stinson J, Thorstad K, Rauch F, Hamdy R, Chougui K, Addab S, Palomo T, Bernstein M, Dahan-Oliel N, Veilleux LN, Massochin Nunes Pinto L, Passos Dos Santos R. Tsimicalis A, et al. JMIR Res Protoc. 2023 Jun 23;12:e47524. doi: 10.2196/47524. JMIR Res Protoc. 2023. PMID: 37351933 Free PMC article.

References

1. Forlino A, Marini JC.. Osteogenesis imperfecta. Lancet. 2016;387(10028):1657–71. doi:10.1016/S0140-6736(15)00728-X. - DOI - PMC - PubMed
1. Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011;7(9):540–57. doi:10.1038/nrendo.2011.81. - DOI - PMC - PubMed
1. Trejo P, Rauch F. Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment. Osteoporosis Int. 2016;27(12):3427–37. doi:10.1007/s00198-016-3723-3. - DOI - PubMed
1. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016;10:CD005088. - PMC - PubMed
1. Hald JD, Evangelou E, Langdahl BL, Ralston SH. Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res. 2015;30(5):929–33. doi:10.1002/jbmr.2410. - DOI - PubMed

LinkOut - more resources

Full Text Sources

[1] Forlino A, Marini JC.. Osteogenesis imperfecta. Lancet. 2016;387(10028):1657–71. doi:10.1016/S0140-6736(15)00728-X. - DOI - PMC - PubMed

[2] Forlino A, Marini JC.. Osteogenesis imperfecta. Lancet. 2016;387(10028):1657–71. doi:10.1016/S0140-6736(15)00728-X. - DOI - PMC - PubMed

[3] Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011;7(9):540–57. doi:10.1038/nrendo.2011.81. - DOI - PMC - PubMed

[4] Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011;7(9):540–57. doi:10.1038/nrendo.2011.81. - DOI - PMC - PubMed

[5] Trejo P, Rauch F. Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment. Osteoporosis Int. 2016;27(12):3427–37. doi:10.1007/s00198-016-3723-3. - DOI - PubMed

[6] Trejo P, Rauch F. Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment. Osteoporosis Int. 2016;27(12):3427–37. doi:10.1007/s00198-016-3723-3. - DOI - PubMed

[7] Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016;10:CD005088. - PMC - PubMed

[8] Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016;10:CD005088. - PMC - PubMed

[9] Hald JD, Evangelou E, Langdahl BL, Ralston SH. Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res. 2015;30(5):929–33. doi:10.1002/jbmr.2410. - DOI - PubMed

[10] Hald JD, Evangelou E, Langdahl BL, Ralston SH. Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res. 2015;30(5):929–33. doi:10.1002/jbmr.2410. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Validation of the Adolescent Pediatric Pain Tool for the Multidimensional Measurement of Pain in Children and Adolescents Diagnosed with Osteogenesis Imperfecta

Affiliations

Validation of the Adolescent Pediatric Pain Tool for the Multidimensional Measurement of Pain in Children and Adolescents Diagnosed with Osteogenesis Imperfecta

Authors

Affiliations

Abstract
in English, French

Conflict of interest statement

Figures

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Abstract in English, French

Conflict of interest statement

Figures

Similar articles

Cited by

References

Related information

LinkOut - more resources

Full Text Sources

Abstract
in English, French